Simultaneous Amplification and Identification of 25 Human Papillomavirus Types with Templex Technology

ABSTRACT The majority of existing human papillomavirus (HPV) genotyping assays are based on multiplex PCR using consensus or degenerate primers. We developed a Templex HPV assay that simultaneously detects and identifies 25 common HPV genotypes in a single-tube reaction using type-specific primers for the HPV-specific E6 and E7 genes. The analytical sensitivities of the Templex assay for HPV type 16 (HPV-16), -18, and -56 were 20, 100, and 20 copies per reaction mixture, respectively. The Templex assay provides semiquantitative information on each type when multiple HPV types coexist in one reaction. We tested 109 clinical cervical specimens previously evaluated with the Digene HC2 high-risk HPV DNA test and found 95.4% concordance between the assay results. The Templex assay provided type-specific results and found multiple types in 29.2% (14 of 48) of high-risk HPV-positive samples. The entire Templex procedure, including DNA extraction, can be completed within 5 hours, providing a rapid and reliable diagnostic tool for HPV detection and typing that is amenable to automation.

[1]  H. Trottier,et al.  Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia , 2006, Cancer Epidemiology Biomarkers & Prevention.

[2]  W. Quint,et al.  Comparison of Two Commercial Assays for Detection of Human Papillomavirus (HPV) in Cervical Scrape Specimens: Validation of the Roche AMPLICOR HPV Test as a Means To Screen for HPV Genotypes Associated with a Higher Risk of Cervical Disorders , 2005, Journal of Clinical Microbiology.

[3]  Daisy R. Lee,et al.  Epidemiologic and viral factors associated with cervical neoplasia in HPV‐16‐positive women , 2005, International journal of cancer.

[4]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[5]  M. Follen,et al.  Human papillomavirus type 16 E2 and E6/E7 variants. , 2005, Gynecologic oncology.

[6]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[7]  D. Wallwiener,et al.  Detection and Typing of Human Papillomavirus by E6 Nested Multiplex PCR , 2004, Journal of Clinical Microbiology.

[8]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[9]  K. Lukaszuk,et al.  Human Papillomavirus Type 16 Status in Cervical Carcinoma Cell DNA Assayed by Multiplex PCR , 2003, Journal of Clinical Microbiology.

[10]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[11]  P. Snijders,et al.  GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes , 2002, Journal of Clinical Microbiology.

[12]  T. Iftner,et al.  Current methods of testing for human papillomavirus. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[13]  A. Mitsuhashi,et al.  Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. , 2001, Gynecologic oncology.

[14]  T. Sasagawa,et al.  A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV). , 2000, Virus research.

[15]  S Wacholder,et al.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.

[16]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[17]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[18]  C. Peyton,et al.  Comparison of PCR- and Hybrid Capture-Based Human Papillomavirus Detection Systems Using Multiple Cervical Specimen Collection Strategies , 1998, Journal of Clinical Microbiology.

[19]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[20]  C. Meijer,et al.  Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes , 1995, Journal of clinical microbiology.

[21]  J. Kaldor,et al.  The causal link between human papillomavirus and invasive cervical cancer: A population‐based case‐control study in colombia and spain , 1992, International journal of cancer.

[22]  William H. Barker,et al.  CLINICAL EPIDEMIOLOGY: THE ESSENTIALS. , 1984 .

[23]  K. Muldrew,et al.  Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a "retest zone". , 2007, American journal of clinical pathology.

[24]  T. Sasagawa,et al.  High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.